Gold Member Since 2015
Audited Supplier
Guangzhou Quanao Chemical Co., Ltd.

Neomycin Sulfate, Antibiotic Veterinary, API manufacturer / supplier in China, offering 99% Neomycin Sulfate for Antibiotic Veterinary CAS 1405-10-3, Tamoxifen Citrate Anabolic Steroids Powder Breast Cancer Health Anti Estrogen Steroids Supplements Cutting Agent, Oral Anobolic Steroids Male Sex Hormone Drugs Anti-Estrogen Steroids Arimidex 120511-73-1 and so on.

(/ )

Supplier Homepage Product Hot Products 99% Neomycin Sulfate for Antibiotic Veterinary CAS 1405-10-3

99% Neomycin Sulfate for Antibiotic Veterinary CAS 1405-10-3

FOB Price: US $1 / Piece
Min. Order: 10 Pieces
Min. Order FOB Price
10 Pieces US $1/ Piece
Get Latest Price
Production Capacity: 1ton/Month
Transport Package: Foil Bags
Payment Terms: T/T, Western Union, Money Gram, Bitcoin

Request a custom order and have something just for you!

Send Customized Request
Basic Info
  • Model NO.: CAS: 1405-10-3
  • Customized: Non-Customized
  • Suitable for: Adult
  • Purity: >99%
  • CAS: 1405-10-3
  • MW: 712.72
  • Specification: GMP
  • HS Code: 3004101110
  • Powder: Yes
  • Certification: GMP, ISO 9001, USP
  • State: Liquid
  • Product Name: Neomycin Sulfate
  • Mf: C23h48n6o17s
  • Trademark: Huao
  • Origin: China
Product Description

99% Neomycin Sulfate for Antibiotic Veterinary CAS 1405-10-3

Product Description
 
99% Neomycin Sulfate for Antibiotic Veterinary CAS 1405-10-3
 
     Neomycin Sulfate Neomycin sulfate
     Neomycin Sulfate CAS: 1405-10-3
     Neomycin Sulfate MF: C23H48N6O17S
     Neomycin Sulfate MW: 712.72
     Neomycin Sulfate EINECS: 215-773-1
     Neomycin Sulfate MP >187° C (DEC. )
     Neomycin Sulfate Refractive index 56 ° (C=10, H2O)
     Neomycin Sulfate Storage temp. 2-8° C
     Neomycin Sulfate Solubility H2O: 50 mg/mL As a stock solution. Stock solutions should be filter sterilized and stored at 2-8° C. Stable at 37° C for 5 days. 
     Neomycin Sulfate Chemical Properties White powder. 
     Neomycin Sulfate Usage antibacterial
     Neomycin Sulfate Usage Neomycin is an aminoglycoside antibiotic found in many topical medications. Neomycin has     been used as a preventive measure for hepatic encephalopathy and hypercholesterolemia. 

 
Neomycin Sulfate Detail description:
 
Neomycin Sulfate Tablets, USP, for oral administration, contain neomycin which is an antibiotic obtained from the metabolic products of the actinomycete Streptomyces fradiae. It has the following molecular formula: C23H46N6O. 2? H2SO4 with a molecular weight of 614.67. 
 
Chemically, it is O-2, 6-diamino-2, 6-dideoxy-a -D- glucopyranosyl(1? 3)-O-b-D- ribofuranosyl-(1? 5) O-[2, 6-diamino-2, 6-dideoxy-a-D-glucopyranosyl-(1? 4)]-2-deoxy-D-streptamine. Neomycin B is identical except that the a- D- glucopyranosyl residue in the neobiosamine moiety is b-L-idopyranosyl. 
 
SYSTEMIC ABSORPTION OF NEOMYCIN OCCURS FOLLOWING ORAL ADMINISTRATION AND TOXIC REACTIONS MAY OCCUR. Patients treated with neomycin should be under close clinical observation because of the potential toxicity associated with their use. NEUROTOXICITY (INCLUDING OTOTOXICITY) AND NEPHROTOXICITY FOLLOWING THE ORAL USE OF NEOMYCIN SULFATE HAVE BEEN REPORTED, EVEN WHEN USED IN RECOMMENDED DOSES. THE POTENTIAL FOR NEPHROTOXICITY, PERMANENT BILATERAL AUDITORY OTOTOXICITY AND SOMETIMES VESTIBULAR TOXICITY IS PRESENT IN PATIENTS WITH NORMAL RENAL FUNCTION WHEN TREATED WITH HIGHER DOSES OF NEOMYCIN AND/OR FOR LONGER PERIODS THAN RECOMMENDED. Serial, vestibular and audiometric tests, as well as tests of renal function, should be performed (especially in highrisk patients). THE RISK OF NEPHROTOXICITY AND OTOTOXICITY IS GREATER IN PATIENTS WITH IMPAIRED RENAL FUNCTION. Ototoxicity is often delayed in onset and patients developing cochlear damage will not have symptoms during therapy to warn them of developing eighth nerve destruction and total or partial deafness may occur long after neomycin has been discontinued. 
 
Neuromuscular blockage and respiratory paralysis have been reported following the oral use of neomycin. The possibility of the occurrence of neuromuscular blockage and respiratory paralysis should be considered if neomycin is administered, especially to patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate anticoagulated blood. If blockage occurs, calcium salts may reverse these phenomena but mechanical respiratory assistance may be necessary. 
 
Concurrent and/or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic and/or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive. 
 
Other factors which increase the risk of toxicity are advanced age and dehydration. 
 
The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. In addition, when administered intravenously, diuretics may enhance neomycin toxicity by altering the antibiotic concentration in serum and tissue. 

 
Neomycin sulfate
CAS: 1405-10-3
MF: C23H48N6O17S
MW: 712.72
EINECS: 215-773-1
MP >187° C (DEC. )
Refractive index 56 ° (C=10, H2O)
Storage temp. 2-8° C
Solubility H2O: 50 mg/mL As a stock solution. Stock solutions should be filter sterilized and stored at 2-8° C. Stable at 37° C for 5 days. 
Chemical Properties White powder. 
Usage antibacterial
Usage Neomycin is an aminoglycoside antibiotic found in many topical medications. Neomycin has been used as a preventive measure for hepatic encephalopathy and hypercholesterolemia. 


Neomycin Sulfate COA:
 



Item

Standard

Result

Characters 

 White to slightly yellow powder, odorless or practically so,

Conforms

Identification 

A.Thin-layer chromatogram meets the requirements

Conforms

B. Positive

Positive 

C. Positive

Positive 

PH

5.0~7.5

6.5

Loss on drying

NMT 8.0%

5.8%

Potency 

NLT 600µg/mg(dried basis)

706µg/mg(dried basis)

665µg/mg(as is)
 

 
Neomycin Sulfate Detail description:
 
Neomycin Sulfate Tablets, USP, for oral administration, contain neomycin which is an antibiotic obtained from the metabolic products of the actinomycete Streptomyces fradiae. It has the following molecular formula: C23H46N6O. 2? H2SO4 with a molecular weight of 614.67. 
 
Chemically, it is O-2, 6-diamino-2, 6-dideoxy-a -D- glucopyranosyl(1? 3)-O-b-D- ribofuranosyl-(1? 5) O-[2, 6-diamino-2, 6-dideoxy-a-D-glucopyranosyl-(1? 4)]-2-deoxy-D-streptamine. Neomycin B is identical except that the a- D- glucopyranosyl residue in the neobiosamine moiety is b-L-idopyranosyl. 
 
SYSTEMIC ABSORPTION OF NEOMYCIN OCCURS FOLLOWING ORAL ADMINISTRATION AND TOXIC REACTIONS MAY OCCUR. Patients treated with neomycin should be under close clinical observation because of the potential toxicity associated with their use. NEUROTOXICITY (INCLUDING OTOTOXICITY) AND NEPHROTOXICITY FOLLOWING THE ORAL USE OF NEOMYCIN SULFATE HAVE BEEN REPORTED, EVEN WHEN USED IN RECOMMENDED DOSES. THE POTENTIAL FOR NEPHROTOXICITY, PERMANENT BILATERAL AUDITORY OTOTOXICITY AND SOMETIMES VESTIBULAR TOXICITY IS PRESENT IN PATIENTS WITH NORMAL RENAL FUNCTION WHEN TREATED WITH HIGHER DOSES OF NEOMYCIN AND/OR FOR LONGER PERIODS THAN RECOMMENDED. Serial, vestibular and audiometric tests, as well as tests of renal function, should be performed (especially in highrisk patients). THE RISK OF NEPHROTOXICITY AND OTOTOXICITY IS GREATER IN PATIENTS WITH IMPAIRED RENAL FUNCTION. Ototoxicity is often delayed in onset and patients developing cochlear damage will not have symptoms during therapy to warn them of developing eighth nerve destruction and total or partial deafness may occur long after neomycin has been discontinued. 
 
Neuromuscular blockage and respiratory paralysis have been reported following the oral use of neomycin. The possibility of the occurrence of neuromuscular blockage and respiratory paralysis should be considered if neomycin is administered, especially to patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate anticoagulated blood. If blockage occurs, calcium salts may reverse these phenomena but mechanical respiratory assistance may be necessary. 
 
Concurrent and/or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic and/or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive. 
 
Other factors which increase the risk of toxicity are advanced age and dehydration. 
 
The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. In addition, when administered intravenously, diuretics may enhance neomycin toxicity by altering the antibiotic concentration in serum and tissue. 
Send your message to this supplier
Avatar
Miss Aimee (Skype: aimee1924@outlook.com)
Whatsapp+8613027196769
*From:
To: Miss Aimee (Skype: aimee1924@outlook.com)
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now

Find Similar Products By Category